Midostaurin: Innovative treatment for blood cancers

Midostaurin, an oral multi-target kinase inhibitor, has become an important treatment for adults with newly diagnosed FMS-like tyrosine kinase-3 (FLT3)-mutated acute myeloid leukemia (AML) and advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with hematological malignancies, and mast cell leukemia).

As the first targeted therapy combined with chemotherapy forAML patients, midostaurin has demonstrated significant efficacy in clinical application. The drug is used together with a companion diagnostic called the LeukoStrat CDx FLT3 mutation test, which can effectively identify FLT3 mutations in AML patients and provide precise guidance for midostaurin treatment. Midostaurin effectively interferes with the growth and spread of cancer cells by inhibiting a variety of enzymes that promote cell growth.

In terms of use, midostaurin is supplied in the form of 25 mg soft capsules. For the treatment of AML, the recommended dose is 50 mg twice daily, taken with food on days 8 to 21 of each induction and consolidation chemotherapy cycle. Subsequently, treatment is continued at a dose of 50 mg as a single agent for up to 12 months. For the treatment of SM, the recommended dose is 100 mg twice daily, taken with food.

However, like other powerful medications, midostaurin may cause some side effects. Common ones include immune system-related problems, such as fever and febrile neutropenia, and blood clotting problems, such as bruising and nosebleeds. In addition, patients may experience nonspecific symptoms such as diarrhea, nausea, and headache. It is important to note that upper respiratory tract infections may pose certain risks. Therefore, when using midostaurin, the patient's response should be closely monitored and the treatment plan adjusted in a timely manner to ensure patient safety.